Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 7/20 | 0.33 |
| ▸ | JAK2 | O60674 | 6/20 | 0.33 |
| ▸ | JAK1 | P23458 | 6/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009009 | 0.80 | OPRM1 (0.35) | OPRM1TRPA1ROCK2PRKG1 | |
| SCHEMBL20012788 | 0.76 | OPRM1 (0.51) | PIK3CDPIK3R1OPRM1TRPA1 | |
| SCHEMBL20009008 | 0.74 | HRH3 (0.35) | PIK3CDPIK3R1OPRM1FGFR1 | |
| SCHEMBL20012579 | 0.72 | OPRM1 (0.38) | OPRM1TRPA1 | |
| SCHEMBL20012580 | 0.68 | OPRM1 (0.46) | PIK3CDPIK3R1TYK2JAK2JAK1 | |
| SCHEMBL19991709 | 0.66 | PDE4B (0.41) | OPRM1ROCK2PRKG1 | |
| SCHEMBL30606886 | 0.66 | OPRM1 (0.50) | OPRM1ROCK2 | |
| SCHEMBL18038663 | 0.66 | OPRM1 (0.50) | OPRM1ROCK2 | |
| SCHEMBL18038762 | 0.63 | GPR119 (0.46) | — | |
| SCHEMBL20012689 | 0.61 | OPRM1 (0.42) | TYK2JAK2JAK1OPRM1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | PIK3CD 3161/4885PIK3R1 508/4885TYK2 3552/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | PIK3CD 3161/4885PIK3R1 508/4885TYK2 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.